MedTrace Logo

Neoadjuvant Chemotherapy in Non Muscle Invasive T1b Bladder Cancer

NCT04245618 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2020-01-30

No results posted yet for this study

Summary

The aim of our study is to evaluate the benefit of NAC in T1b NMIBC .

Conditions

Interventions

DRUG

neoadjuvant chemotherapy ( cisplatin - gemcitabine)

Neoadjuvant chemotherapy before TURBT

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • hoda essa, professor · Assiut University

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-31
Primary Completion
2021-07-31
Completion
2021-09-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04245618 on ClinicalTrials.gov